Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer

Loss of heterozygosity (LOH) at 6q is a frequent chromosomal aberration in prostate adenocarcinoma; however, a possible target gene remains to be identified. Findings in this study indicate that the FYN tyrosine kinase gene at 6q21 is a new candidate tumor suppressor in prostate cancer. Initially, single nucleotide polymorphism microarray analysis of 40 microdissected prostate adenocarcinoma samples revealed 25% LOH at the FYN locus. Furthermore, Western blot analysis and real‐time reverse transcriptase PCR (RT‐PCR) showed significantly lower FYN expression in prostate cancer tissue than in benign prostate hyperplasia (BPH), as well as in 6 prostate adenocarcinoma cell lines compared with that in BPH‐1 cells. By immunohistochemistry, FYN protein was detected in nonmalignant prostate epithelium, but not in cancerous glands. Moreover, genomic bisulfite sequencing revealed frequent aberrant methylation of a large CpG island in the FYN promoter region in both adenocarcinoma cell lines (3 of 5 cell lines tested) and primary prostate cancer (12 of 18 tumors). Methylation was generally of moderate density, affecting preferentially the 3′ region of the CpG island. Dense hypermethylation of the entire CpG island, consistent with gene silencing, was detected in 2 of 18 tumors (11%). No methylation was found in BPH‐1 cells or nonmalignant prostate tissue samples (0 of 7). These results indicate that FYN is downregulated in prostate cancer by both chromosomal deletion and promoter hypermethylation, and therefore is a novel prostate tumor suppressor gene candidate. © 2007 Wiley‐Liss, Inc.

[1]  K Offit,et al.  6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. , 1993, Blood.

[2]  M. Fournel,et al.  Oncogenic activation of p59fyn tyrosine protein kinase by mutation of its carboxyl-terminal site of tyrosine phosphorylation, tyrosine 528. , 1994, The Journal of biological chemistry.

[3]  A. Veillette,et al.  Unique catalytic properties dictate the enhanced function of p59fynT, the hemopoietic cell-specific isoform of the Fyn tyrosine protein kinase, in T cells , 1994, Molecular and cellular biology.

[4]  C. Hsieh,et al.  Dependence of transcriptional repression on CpG methylation density , 1994, Molecular and cellular biology.

[5]  T. Visakorpi,et al.  Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. , 1995, Cancer research.

[6]  O. Cussenot,et al.  Recurrent cytogenetic alterations of prostate carcinoma and amplification of c‐myc or epidermal growth factor receptor in subclones of immortalized pnt1 human prostate epithelial cell line , 1995, International journal of cancer.

[7]  C. Theillet,et al.  Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: possibly four regions of deletion. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  M. Cohen,et al.  Fas-mediated apoptosis in human prostatic carcinoma cell lines. , 1997, Cancer research.

[9]  Sheila M. Thomas,et al.  Cellular functions regulated by Src family kinases. , 1997, Annual review of cell and developmental biology.

[10]  T. Visakorpi,et al.  Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. , 1998, Cancer genetics and cytogenetics.

[11]  P. Auberger,et al.  Cleavage and relocation of the tyrosine kinase P59FYN during Fas-mediated apoptosis in T lymphocytes , 1999, Oncogene.

[12]  J. Herman,et al.  p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. , 1999, Blood.

[13]  K. Kok,et al.  Substantial reduction of the gastric carcinoma critical region at 6q16.3-q23.1. , 1999, Genes, chromosomes & cancer.

[14]  K. Kok,et al.  Substantial reduction of the gastric carcinoma critical region at 6q16.3–q23.1 , 1999 .

[15]  J. Herman,et al.  Methylation Patterns of the E-cadherin 5′ CpG Island Are Unstable and Reflect the Dynamic, Heterogeneous Loss of E-cadherin Expression during Metastatic Progression* , 2000, The Journal of Biological Chemistry.

[16]  J. Welsh,et al.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.

[17]  V. Lang,et al.  An absolute requirement for Fyn in T cell receptor‐induced caspase activation and apoptosis , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[19]  M. Bittner,et al.  Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. , 2001, Cancer research.

[20]  M. Schartl,et al.  Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. , 2002, The Journal of biological chemistry.

[21]  E. Latulippe,et al.  Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. , 2002, Cancer research.

[22]  Holger Christiansen,et al.  Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. , 2002, Cancer cell.

[23]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[24]  H. Frierson,et al.  Defining the region(s) of deletion at 6q16–q22 in human prostate cancer , 2002, Genes, chromosomes & cancer.

[25]  T. Atkinson,et al.  Identification of an alternatively spliced isoform of the fyn tyrosine kinase. , 2002, Biochemical and biophysical research communications.

[26]  Takeshi Suzuki,et al.  New genes involved in cancer identified by retroviral tagging , 2002, Nature Genetics.

[27]  Rachel Jones,et al.  Behavioural genetics: Worms gang up on bacteria , 2002, Nature Reviews Genetics.

[28]  M. Schartl,et al.  Activation of p59Fyn Leads to Melanocyte Dedifferentiation by Influencing MKP-1-regulated Mitogen-activated Protein Kinase Signaling* , 2002, The Journal of Biological Chemistry.

[29]  M. Emmert-Buck,et al.  Loss of heterozygosity on chromosome arms 3p and 6q in microdissected adenocarcinomas of the uterine cervix and adenocarcinoma in situ , 2002, Cancer.

[30]  R. Sakai,et al.  Cooperative Roles of Fyn and Cortactin in Cell Migration of Metastatic Murine Melanoma* , 2003, Journal of Biological Chemistry.

[31]  Anton Berns,et al.  Retroviral insertional mutagenesis: tagging cancer pathways. , 2003, Advances in cancer research.

[32]  Rajiv Dhir,et al.  Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors , 2005, BMC Cancer.

[33]  Luc Girard,et al.  An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. , 2004, Cancer research.

[34]  G. Gallick,et al.  Src family kinases in tumor progression and metastasis , 2003, Cancer and Metastasis Reviews.

[35]  Y. Pak,et al.  In vitro methylation of nuclear respiratory factor-1 binding site suppresses the promoter activity of mitochondrial transcription factor A. , 2004, Biochemical and biophysical research communications.

[36]  C. Downes,et al.  PTEN function: how normal cells control it and tumour cells lose it. , 2004, The Biochemical journal.

[37]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Takeshi Suzuki,et al.  RTCGD: retroviral tagged cancer gene database , 2004, Nucleic Acids Res..

[39]  M. Becich,et al.  Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[41]  J. Olson,et al.  Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer , 2005, Oncogene.

[42]  T. Ørntoft,et al.  Secretagogin Is a Novel Marker for Neuroendocrine Differentiation , 2006, Neuroendocrinology.

[43]  M. Tatematsu,et al.  Chemical genomic screening for methylation‐silenced genes in gastric cancer cell lines using 5‐aza‐2′‐deoxycytidine treatment and oligonucleotide microarray , 2006, Cancer science.

[44]  F. Bertoni,et al.  Chromosome band 6q deletion pattern in malignant lymphomas. , 2006, Cancer genetics and cytogenetics.

[45]  E. Gelmann,et al.  Molecular biology of prostate-cancer pathogenesis , 2006, Current opinion in urology.

[46]  K. D. Sørensen,et al.  Genome-wide analysis of allelic imbalance in prostate cancer using the Affymetrix 50K SNP mapping array , 2007, British Journal of Cancer.